NCT00744679已完成4 期
An Assessment of the Steady-State Pharmacokinetic and Pharmacodynamic Profile of Tysabri 300 mg Following at Least 12 Monthly Infusions
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Biogen
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Pharmacokinetic (PK) Profile of Natalizumab
研究概览
简要总结
The primary objective is to assess the pharmacokinetic (PK) profile of natalizumab (Tysabri) at steady state.
The secondary objective is to assess the pharmacodynamics (PD) profile (α4 integrin saturation) of Tysabri at steady state.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
- •Must be a multiple sclerosis (MS) patient enrolled in the Tysabri Outreach: United Commitment to Health Prescribing Program (TOUCH) who is not expected to discontinue Tysabri therapy prior to completion of the requirements of this study.
- •Must have been treated with monthly IV infusions of Tysabri 300 mg for at least 12 months, with the 9 most recent doses having been administered at 28±7 day intervals.
- •Must test negative for antibodies to Tysabri at the Screening Visit.
- •Must have a magnetic resonance imaging (MRI) brain scan, performed prior to the initiation of treatment with Tysabri, on file.
- •Must weigh between 42 and 126 kg, inclusive.
- •All male subjects and female subjects of childbearing potential must practice effective contraception during the study.
排除标准
- •History of, or abnormal laboratory results indicative of, any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, and renal, or other major disease, as determined by the Investigator.
- •Positive result for antibodies to Tysabri at any prior evaluation.
- •Treatment with an investigational product or approved therapy for investigational use within 6 months prior to the start of PK sample collection or during the course of this study. Concurrent participation in an observational study (e.g., Tysabri Global Observational Program in Safety [TYGRIS]) is permitted.
- •Pre-scheduled for any elective procedure or medical treatment during the study period.
- •History of drug or alcohol abuse (as defined by the Investigator) within 2 years prior to the Screening Visit.
- •Female subjects who are breastfeeding, pregnant, or planning to become pregnant while on study.
- •Alcohol use within 24 hours prior to the Baseline Visit.
- •Inability or unwillingness to comply with study requirements, including the presence of any condition (e.g., physical, mental, social) that is likely to affect the subject's ability to comply with the study protocol.
- •Other unspecified reasons that, in the opinion of the Investigator or Biogen Idec, make the subject unsuitable for enrollment.
- •NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
研究组 & 干预措施
Natalizumab 300 mg
Experimental
Natalizumab infused at 300 mg every 28 days during the screening and assessment periods of the study which continues the therapy of the previous 12 months and maintains steady-state pharmacokinetics.
干预措施: Natalizumab (Drug)
结局指标
主要结局
Pharmacokinetic (PK) Profile of Natalizumab
时间窗: Baseline (Day 0), 2 hours after infusion starts on Days 1 and on Days 2, 3, 4, 7, 14, 21 and 28
次要结局
- Natalizumab Binding Saturation Of α4 Integrin Sites On Peripheral Blood Mononuclear Cells (PBMC).(Baseline (Day 0), 2 Hours after infusion starts on Days 1, and on Days 4, 7, 14, 21 and 28)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Assess Blood Levels of Itraconazole During a Two-Week PeriodHealthyNCT00695071Stiefel, a GSK Company16
终止
2 期
Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) InfectionHepatitis C Virus InfectionNCT03820258Gilead Sciences21
已完成
1 期
Pharmacokinetic Study of Thalidomide in Subjects With Multiple MyelomaMultiple MyelomaNCT01937442Celgene7
已完成
1 期
Study of Pharmacokinetics and Pharmacodynamics of Artesunate in Pregnant Women in the Democratic Republic of CongoMalariaNCT00538382NICHD Global Network for Women's and Children's Health51
已完成
4 期
Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)Relapsing-Remitting Multiple SclerosisNCT02142205Biogen100